STAT May 8, 2024
Ed Silverman

Hello, everyone, and welcome to the middle of the week. Congratulations on making it this far, because it is an accomplishment, after all. The next step, of course, is to somehow forge ahead. And why not? Just consider the alternatives. On that optimistic note, please join us for a needed cup or three of stimulation. Our choice today is salted caramel, which reminds us of the breezy Jersey shore. Meanwhile, here are some items of interest to get you going. Have a wonderful day, and do drop us a line when you hear something juicy. …

A young boy died in a trial for an experimental Pfizer gene therapy for Duchenne muscular dystrophy, STAT writes, citing a note that was...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma, Pharma / Biotech
CNS-Focused Rapport Therapeutics Preps IPO to Back Phase 2-Ready Epilepsy Drug
Balancing Weight-loss Medication Cost and Care
Marijuana rescheduling moves businesses into ‘uncharted territory’
Orforglipron: the new kid on the GLP-1 block
Reimagining Healthcare Delivery - 2

Share This Article